Assertio Holdings, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ASRT Nasdaq 2834 www.assertiotx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Assertio Holdings, Inc.

Q1 2025 Assertio Holdings Inc Earnings Call - May 13th, 2025 9:38 am
Assertio Holdings Inc (ASRT) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... - May 13th, 2025 7:09 am
Assertio: Q1 Earnings Snapshot - May 12th, 2025 8:20 pm
Assertio Reports First Quarter 2025 Financial Results - May 12th, 2025 8:01 pm
Assertio Holdings, Inc. to Report First Quarter 2025 Financial Results on May 12, 2025 - May 5th, 2025 12:15 pm
iAccess Alpha's Virtual Best Ideas Spring Investment Conference March 25-26, 2025 - Mar 21st, 2025 1:00 pm
Assertio to Participate in the iAccess Alpha Virtual Best Ideas Conference on March 25-26, 2025 - Mar 20th, 2025 1:10 pm
Assertio Holdings Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Mar 14th, 2025 11:11 am
Q4 2024 Assertio Holdings Inc Earnings Call - Mar 13th, 2025 4:58 pm
Assertio Holdings Inc (ASRT) Q4 2024 Earnings Call Highlights: Strategic Growth Amidst Challenges - Mar 13th, 2025 7:08 am
Assertio: Q4 Earnings Snapshot - Mar 12th, 2025 8:30 pm
Assertio Reports Fourth Quarter and Full Year 2024 Financial Results - Mar 12th, 2025 8:05 pm
Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025 - Mar 5th, 2025 9:05 pm
Investors in Assertio Holdings (NASDAQ:ASRT) have unfortunately lost 87% over the last five years - Feb 2nd, 2025 1:13 pm
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Jan 3rd, 2025 9:30 pm
Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors - Dec 17th, 2024 1:30 pm
Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study - Dec 13th, 2024 1:00 pm
Assertio Holdings, Inc. Appoints Paul Schwichtenberg to New CTO Role, Mary Pietryga as CCO - Dec 12th, 2024 1:00 pm
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer - Dec 6th, 2024 12:00 pm
Assertio Holdings Third Quarter 2024 Earnings: Beats Expectations - Nov 13th, 2024 10:27 am